Figures & data
Figure 1 Flowchart of the study population.
Table 1 Characteristics of analytical populations
Table 2 Agreement between MoBa and NorPD by trimester, pregestational period, and gestational period
Figure 2 Adherence patterns of four-group trajectories.
Abbreviations: C-H, Constant-High; C-M, Constant-Medium; D-L, Decreasing-Low; I-M, Increasing-Medium.
Table 3 Maternal characteristics among the adherence groups
Table 4 Drug utilization in the adherence groups
Table 5 Multivariate crude and adjusted OR for Decreasing-Low (n=70)Table Footnotea vs other THRT trajectory (n=1,101)
Figure S1 Timeline of questionnaires (MoBa) and of prescription records (NorPD).
Notes: MoBa Q1, completed in gestational week 17, covers medication use in early pregnancy. MoBa Q2 is a dietary questionnaire filled out around gestational week 22 and was not included in this study. MoBa Q3, completed in gestational week 30, covers medication use in mid pregnancy. MoBa Q4, completed 6 months after delivery, covers medication use in last part of pregnancy and during the first 6 months after delivery. We did not include the first 6 months after delivery covered by MoBa Q4 in our analysis.
Abbreviations: GW, gestational week; LMP, last menstrual period; MoBa, Norwegian Mother and Child Cohort Study; MoBa Q1, MoBa questionnaire 1; MoBa Q2, MoBa questionnaire 2; MoBa Q3, MoBa questionnaire 3; MoBa Q4, MoBa questionnaire 4; NorPD, Norwegian Prescription Database.
Table S1 Calculation of sensitivity, specificity, PPV, and NPVTable Footnotea
Table S2 Agreement between MoBa and NorPD for 4-week intervals in MoBa Q1 and MoBa Q3
Table S3 Model selection using BIC criterion, and estimated group proportions